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Summary
Objective: As part of the National Institutes of Health (NIH)-sponsored Glucosamine/Chondroitin sulfate Arthritis Intervention Trial (GAIT) our
objective here was to examine (1) the pharmacokinetics (PK) of glucosamine (GlcN) and chondroitin sulfate (CS) when taken separately or in
combination as a single dose in normal individuals (n¼ 29) and (2) the PK of GlcN and CS when taken as a single dose after 3 months daily
dosing with GlcN, CS or GlcNþCS, in patients with symptomatic knee pain (n¼ 28).
Methods: The concentration of GlcN in the circulation was determined by established ﬂuorophore-assisted carbohydrate electrophoresis
(FACE) methods. The hydrodynamic size and disaccharide composition of CS chains in the circulation and dosage samples was determined
by Superose 6 chromatography and FACE.
Results: We show that circulating levels of CS in human plasma are about 20 mg/ml. Most signiﬁcantly, the endogenous concentration and CS
disaccharide composition were not detectably altered by ingestion of CS, when the CS was taken alone or in combination with GlcN. On the
other hand, the Cmax (single-dose study) and AUC values (multiple-dose study) for ingested GlcN were signiﬁcantly reduced by combination
dosing with CS, relative to GlcN dosing alone.
Conclusions: We conclude that pain relief perceived following ingestion of CS probably does not depend on simultaneous or prior intake of
GlcN. Further, such effects on joint pain, if present, probably do not result from ingested CS reaching the joint space but may result from
changes in cellular activities in the gut lining or in the liver, where concentrations of ingested CS, or its breakdown products, could be sub-
stantially elevated following oral ingestion. Moreover, since combined dosing of GlcN with CS was found to reduce the plasma levels seen
with GlcN dosing alone, any improved pain relief by combination dosing cannot be explained by higher circulating concentrations of GlcN.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is the most common form of arthritis in
the United States and is projected to double in prevalence
within the next two decades1. Its pathogenesis remains un-
known but is currently thought to be a complex interaction of
biologic (inﬂammation, ﬁbrosis) and mechanical processes
resulting in failure of the articular cartilage2. The potential
for true disease modiﬁcation is uncertain and limits the pres-
ent rationale for pharmacologic intervention in the manage-
ment of OA to relief of symptoms3. The use of
acetaminophen, alone or in combination with a nonsteroidal
anti-inﬂammatory drug is recommended as initial therapyaDrs Christopher Jackson and Anna Plaas contributed equally to
this study.
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297but the utility of these traditional agents is limited due to
marginal efﬁcacy and/or toxicity4. There is considerable in-
terest in GlcN and CS in treating OA but no consensus ex-
ists as to the proper role of these nutriceuticals as existing
clinical studies have yielded disparate results, perhaps due
in part to the use of different formulations of these agents5.
Further, the daily dosages and dosing regimens employed
have been largely empiric because of scant pharmacologic
information. The recently completed Glucosamine/chon-
droitin Arthritis Intervention Trial (GAIT) was a 24-week,
National Institutes of Health (NIH)-sponsored, double blind,
placebo controlled parallel trial comparing GlcN.HCl,
500 mg (3 per day) with CS, 400 mg (3 per day) alone
and in combination, with celecoxib 200 mg daily and pla-
cebo as positive and negative controls, respectively. We
found that no regimen (GlcN alone, CS alone or the two
combined) was superior to placebo in pain relief but beneﬁt
from the combination was suggested in a pre-speciﬁed sub-
set having more severe knee pain. Radiographic evidence
of disease modiﬁcation was not observed6. Herein we
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Fig. 1. FACE analyses of the CS in fractions from Superose 6 chro-
matography. Disaccharide analysis is shown for Superose fractions
(9e19) derived from 1 ml of proteinase K-digested plasma from
a typical naive patient (A) and a normal patient after a single dos-
age of CS alone (B). The naive patient was from the Phase 1 study
and the single CS dosage from Phase 2.This investigation was conducted in three phases as follows: In Phase 1,
the presence and diurnal variation of endogenous plasma levels of GlcN and
CS were determined by obtaining blood samples from 14 na€ıve subjects. Fol-
lowing an overnight fast, samples were obtained at 0800 and 2, 4, 8, and
24 h thereafter. The demographic characteristics for this group are shown
in Table I. In Phase 2, the single-dose PK of GlcN and CS were determined
from concentration-time data obtained from 29 normal human subjects who
were randomized to receive either 1500 mg of GlcN.HCl (six capsules con-
taining 250 mg each; eight subjects), 1200 mg of CS (six capsules containing
200 mg each; 10 subjects), or the combination of GlcN and CS (11 subjects).
Following an overnight fast, the study medication was ingested at 08:00 and
blood samples were obtained at 0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 2.5, 3, 4,
6, 8, 12, 24, and 36 h following ingestion. The demographics for this group
are shown in Table III. In Phase 3, the PK of GlcN and CS were determined
from concentration-time data in 28 subjects, age 40 and older with symptom-
atic knee pain. The plasma samples were obtained over a 36 h interval fol-
lowing single dosage of GlcN or CS, which was taken following 3 months
of daily ingestion of either GlcN (500 mg, three times per day, nine subjects),
CS (400 mg, three times per day, nine subjects) or the combination (10 sub-
jects). At the end of the 3 months and following an overnight fast, the med-
ication (either GlcN or CS) was ingested at 08:00 and blood samples were
obtained at 0, 1, 1.5, 2, 4, 6, 8, 12, 24, and 36 h following ingestion. The de-
mographics for this group are shown in Table V.ANALYTICAL METHODS FOR QUANTITATION OF PLASMA
GLCN AND CSThe concentration of GlcN in all phases of this study was determined by
a ﬂuorophore-assisted carbohydrate electrophoresis (FACE) method used
previously to measure GlcN in horse serum7. While our method7,8 and
a mass spectrometric method9 were unable to detect endogenous glucos-
amine (GlcN) in the circulation (limit of detection about 10 ng/ml), others
have reported endogenous concentrations up to about 50 ng/ml in both hu-
mans10 and horses11. For CS, blood was collected into heparinized tubes
and plasma samples (1 ml portions) were delipidated with LiposorbTM (Cal-
biochem) and deproteinized by digestion with proteinase K. After boiling for
5 min, insoluble material was removed by centrifugation. Clariﬁed superna-
tants (containing all CS components) were mixed with 10,000 cpm 3H-glu-
cose, prior to fractionation on Superose 6 [High resolution (HR)30/30] at
0.5 ml/min in 100 mM ammonium bicarbonate. Fractions collected at the total
volume of each run were analyzed for 3H-glucose content and the precise %
recovery (generally 75e80%) was taken as the recovery of all CS compo-
nents and was incorporated into the ﬁnal calculation of plasma contents.
The CS assay was also validated by ‘‘spiking’’ normal plasma samples
with CS (in the form used in oral dosages) and determining the percent re-
covery through the assay procedure. This was routinely greater than 75%.
For total CS quantitation, samples eluted in fractions 9e19 (see Fig. 1 for
analysis of individual fractions by FACE) were pooled, speedvac dried, res-
idues washed twice by resuspension in water and drying. Final residues
were digested in 0.5 ml of 0.1M ammonium acetate, pH 7.3 and digested
with Chondroitinase ABC (0.025 units) for 16 h at 37. Dried samples were
ﬂuoro-tagged with 5 ml of 2-aminoacridone (AMAC), separated on acrylamide
gels (29.3% separating and 5% stacking) and the ﬂuorescent products were
imaged using a Kodak 1D Scientiﬁc Imaging System at 0.01 s, 0.1 s, 0.25 s,
0.5 s, 0.75 s and 1.5 s exposures on a Ultra-violet Products (UVP) High Per-
formance Ultra violet Transilluminator. Band intensities were converted into
concentrations based on ﬂuoro-tagged disaccharide standards as pub-
lished8. The plasma concentration e time data were analyzed by standardTable I
Demographic characteristics of Phase 1 subjects (MeanSD)
Number of subjects 14
Weight (kg) 84.2 20.6
Height (cm) 172 17.2
Age (years) 41.4 17.9
Gender (male/female) 7/7methods to determine the human PK of GlcN7. Statistical comparisons
were made between groups within Phase 2 and 3 using Student’s t-test
with statistical signiﬁcance determined at P  0.05.ResultsANALYSIS OF CS IN HUMAN PLASMAThe concentration of CS in mammalian plasmas, includ-
ing human, have been widely reported at 5e20 mg/ml.12,13
Because of this, determining the plasma concentration of in-
gested CS required analysis of both the structure (polymer
size, disaccharide isomer composition) and the total con-
centration of CS (as disaccharides) in the pre-dose and
post-dose plasma samples. For this purpose, we developed
a protocol (see Methods for detail) which includes size frac-
tionation (Superose 6) of the CS in proteinase K-digested
plasma, followed by FACE determination of the CS disac-
charide composition (Ddi0S, Ddi4S, Ddi6S) and abundance.
Importantly, the Superose 6 step removes essentially all the
plasma glucose which at about 4 mg/ml interferes with the
FACE quantitation of the low abundance CS disaccharides.
FACE analyses is shown for the plasma CS in the Super-
ose fractions (9e19) derived from a typical naive patient
[Fig. 1(A)] and a normal patient, 3 h after a single
1200 mg dose of CS alone [Fig. 1(B)]. For both individuals
the Superose 6 resolved the CS chains present in protein-
ase K-digested plasma samples into two populations. A
very minor high molecular weight CS chain population,
composed of Ddi4S only, eluted between fractions 10e13;
the majority of plasma CS however was in a lower molecu-
lar weight form (fractions 15e20), and these chains were
composed of w60% Ddi0S, w30% Ddi4S and w10%
Ddi6S. The relative abundance (pixel density per 0.25 s ex-
posure) of each disaccharide in fractions 8e19 from the na-
ive patient [Fig. 2(A)], and the single CS dosage patient
[Fig. 2(B)], is given along with the same fractionation and
FACE analysis of the CS used in the oral dosing
[Fig. 2(C)]. This shows that a single CS dose resulted in
no detectable change in either the hydrodynamic size or di-
saccharide composition of the plasma CS, 3 h after dosing.
Indeed the same result was found for plasma samples
taken at all time periods after dosing from 0.25 h to 36 h.
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Fig. 2. Quantitation of CS disaccharides in Superose 6 fractions
abundance of CS (as disaccharides) in the Superose fractions
(8e19) derived from 1 ml of proteinase K-digested plasma from
a typical naive patient (A) and a normal patient after a single dos-
age of CS alone (B). The naive patient was from the Phase 1 study
and the single CS dosage from Phase 2. Also shown (C) is the
same analysis of the CS used for oral dosing. Ddi4S (closed
circles), Ddi6S (closed triangles), Ddi0S (open squares).
Table III
Demographics for the 29 normal subjects in Phase 2 (MeanSD)
Dosing regimen GlcN CS GlcNþCS
Number of subjects 8 10 11
Weight (kg) 76.8 13.2 76.2 22.4 83.9 23.4
Height (cm) 178 8.1 169 9.4 173 6.9
Age (years) 32.3 12.0 37.8 18.3 34.2 10.5
Gender (male/female) 6/2 2/8 4/7
299Osteoarthritis and Cartilage Vol. 18, No. 3Moreover, the hydrodynamic size proﬁle and the disaccha-
ride composition (w45% Ddi4S, w45% Ddi6S, w10%
Ddi0S) of the CS used for dosing [Fig. 2(C)] were both dis-
tinct from the CS chains recovered in the post-hepatic circu-
lation under all oral dosing regimes employed in this study.PK DATA FOR PLASMA GlcN AND CS IN SUBJECTS FROM
EACH DOSING STUDYBaseline plasma levels of GlcN and CS were determined
at ﬁve times throughout a single day (Table II). GlcN was
undetectable at every time point whereas the level of CS
was approximately 19 mg/ml with no apparent diurnal ﬂuctu-
ation. To examine the possible effect of combined dosing
on the PK for GlcN, the time-concentration proﬁle for a sin-
gle dose of GlcN taken alone or in combination with CS wasTable II
Baseline plasma levels of GlcN and CS in Phase 1 subjects
(MeanSD)
Time GlcN (ng/mL) CS (mg/mL)
0 hours (0800) <limit of detection 20.8 10.5
2 h <limit of detection 18.9 10.3
4 h <limit of detection 17.7 11.2
8 h <limit of detection 19.5 9.11
24 h <limit of detection 18.7 9.15obtained (Fig. 3). This revealed no major effect of combined
dosing. The overall PK data [Mean standard deviation
(SD)] for 8 individuals taking GlcN alone and eleven individ-
uals taking the combination dosage is provided in Table IV.
The Cmax for GlcN when dosed alone (about 490 ng/ml),
was signiﬁcantly (P< 0.05) higher than that observed with
combined dosing (about 310 ng/ml), however there was
no signiﬁcant difference in any of the other PK parameters
determined. The possible cumulative effect of 3 months of
pre-dosing with GlcN or GlcNþCS, on the PK of GlcN
was also examined. It was found that the concentration pro-
ﬁle for plasma GlcN was essentially identical for the two
pre-dosing schedules (Fig. 4). The overall PK data
(MeanSD) for a single dose of GlcN after 3 months
pre-dosing with GlcN or GlcNþCS is provided in Table VI.
It was found that the Area under Curve (AUC) for GlcN was
signiﬁcantly lower for the combination predosage relative to
pre-dosing with GlcN alone, however there were no signiﬁ-
cant differences in the other PK parameters determined for
these two groups.
The possible effect of combined dosing on the concentra-
tion proﬁle for plasma CS was studied next (Fig. 5). It was
found that the plasma concentration of CS for 24 h following
a single dose of CS (1200 mg), taken alone or in combina-
tion with 1500 mg of GlcN, was not affected by the com-
bined dosing. In both cases the CS concentration was not
detectably different from baseline levels. Finally, the possi-
ble cumulative effect of 3 months of pre-dosing with GlcN,
CS or GlcNþCS, on the plasma levels after a single
1200 mg dose of CS was also examined (Fig. 6). While
there appeared to be a trend towards higher CSFig. 3. The effect of combined dosing on the concentration proﬁle
for plasma GlcN in a normal individual. The plasma concentration
of GlcN following a single dose of GlcN (1500 mg) taken alone
(open diamonds) or in combination with 1200 mg CS (closed
squares) is shown. Without dosing the plasma GlcN was
undetectable (open triangles).
Table IV
PK data (Mean SD) for single-dose GlcN when taken alone or
with CS in Phase 2
Parameter GlcN GlcNþCS
AUCN (ng hr/mL)* 2380 935 1860 892
Cmax (ng/mL)y 492 161 311 103*
Tmax (h) 2.31 1.19 2.05 1.33
Tlag(h) 0.29 0.23 0.26 0.18
t, abs (h) 0.86 0.56 0.77 0.85
t,el(h) 2.51 1.84 2.90 2.50
P< 0.05.
*AUC determined by trapezoidal rule with extrapolation to inﬁnity.
yCmax and Tmax taken directly from data.
Fig. 4. The effect of pre-dosing on the concentration proﬁle for
a single dose of GlcN The plasma concentration of GlcN following
a single dose of GlcN (1500 mg) after 3 months of pre-dosing with
300 C. G. Jackson et al.: Pharmacokinetics of oral glucosamine and chondroitin sulfateconcentrations following pre-dosing with GlcNþCS, these
values were not signiﬁcantly different from the other groups
assayed.GlcN (open diamonds) or GlcNþCS (closed squares).Discussion
It has been suggested, without extensive data support,
that the effectiveness of oral GlcN or CS in providing pain
relief from OA might depend on combined and/or long-
term dosing6,14e17. This idea implies that there is likely to
be a synergistic effect on absorption, PK or cell biological
activity for these two agents when taken orally over ex-
tended periods. In this study with human patients from the
GAIT study, we have examined the possibility that com-
bined short or long-term dosing might alter the PK proﬁle
for these two agents.WE FOUND NO EVIDENCE FOR ABSORPTION OF ORAL CS
INTO THE CIRCULATION UNDER ANY DOSING REGIMENTable VIWe have been unable to detect any of the dietary CS in
the circulation under any dosing condition used; these con-
ditions involved both long-term (3 months) and acute dos-
ing, both alone and in combination with GlcN. The
sensitivity of the FACE analysis used for CS disaccharide
analysis is sufﬁcient to detect product at about 10 ng/ml.
Therefore, if the absorption of CS into the circulation was
similar to that which has been established for the same
dose of GlcN, the Cmax for plasma CS (or its disaccharide
and larger breakdown products) would be at about 200 ng/
ml. However, our compositional analysis of the plasma at
multiple time points up to 24 h after dosing, showed no
change in the content of C6S disaccharide, which repre-
sents about 45% of the dosage compound but less than
10% of the endogenous CS (see Fig. 1). We therefore con-
clude that little, if any, of the ingested CS reaches the circu-
lation in a form which is unchanged or composed of
disaccharides or larger fragments. On the other hand, our
quantitative determination would likely not detectTable V
Demographics for the 28 subjects with knee pain in Phase 3
(MeanSD)
Dosing regimen GlcN CS GlcNþCS
Number of subjects 10 9 9
Weight (kg) 100 27.1 97.7 20.9 89.6 27.3
Height (cm) 172 11.0 168.0 3.7 173 2.7
Age (years) 56.3 8.60 55.2 9.2 58.0 9.9
Gender (male/female) 5/5 3/6 3/6a 200 ng/ml change in total CS since, in keeping with
others13,18 we found the endogenous CS concentration to
be about 20 mg/ml and this baseline can vary in an individ-
ual by about 5 mg/ml throughout the day (see Fig. 6). In this
regard, it is likely that the major source for plasma CS is the
circulating serine proteinase inhibitor, bikunin-CS, which
has been measured at about 11 mg/ml in human plasma19.
Indeed, our ﬁnding that the disaccharide composition of CS
in baseline human plasma samples was largely unsulfated
disaccharide of chondroitin sulfate (OS) and 4S disaccha-
rides is consistent with a major contribution from bikunine
CS20. Other potential sources of plasma CS sulfate are ﬁ-
broblast and/or chondrocyte CSeproteoglycans, such as
versican and aggrecan, released from the tissue into the
plasma as part of normal turnover processes.THE Cmax FORGlcNWAS HIGHERWHEN THEGlcNWAS TAKEN
ALONE COMPARED TO COMBINATION DOSING WITH CSIn the present study the Cmax values for GlcN taken alone
(492 160 ng/ml) were signiﬁcantly higher than when the
GlcN was taken with CS (311 103 ng/ml). Further, when
GlcN was taken alone in multiple doses, the AUC values for
a single dose (1870 638ng hr/mL)were signiﬁcantly higher
than when the GlcN was taken in multiple doses with CS
(1,099.0 466.0 ng hr/mL) (Table IV). These ﬁndings sug-
gest that including CS with GlcN ingestion interferes with
GlcN absorption into the circulation, which occurs via the glu-
cose transporter system and involves both sodium-depen-
dent glucose transporter (SGLT)1 and glucose transporterPK data (MeanSD) for single-dose GlcN when taken after 3
months of multiple dosing of either GlcN or GlcN plus CS (Phase 3)
Parameter GlcN GlcNþCS
AUCN (ng hr/mL)* 1,870 638 1,099 466*
Cmax (ng/mL)y 211 93.1 217 72.8
Tmax (h) 2.25 0.98 2.80 1.3
Tlag(h) 0.29 0.23 0.260 0.180
t,el(h) 3.94 2.45 2.42 1.82
*P< 0.05.
*AUC determined by trapezoidal rule with extrapolation to inﬁnity.
yCmax and Tmax taken directly from data.
Fig. 5. The effect of combined dosing on the concentration proﬁle
for plasma CS. The plasma concentration of CS following a single
dose of CS (1200 mg) taken alone (ﬁlled diamonds) or in combina-
tion with 1500 mg of GlcN (closed square) is shown. Also shown is
control data without CS dosing (closed triangles).
301Osteoarthritis and Cartilage Vol. 18, No. 3(GLUT)-221. Such an inhibitory effect supports the notion that
dietary CS impacts the metabolism of gut lining cells and in
this regard it would be interesting to determine whether it
can inhibit either of the glucose transporters responsible for
G absorption.SUMMARYThe data provided suggest that the variable pain relief ap-
parently experienced by OA patients following ingestion of
GlcN, CS or the two in combination cannot be readily ex-
plained by synergistic effects of the two agents on intestinal
absorption. This follows from the ﬁnding that absorption of
dietary CS is undetectable whether it is taken alone or
with GlcN, and absorption of GlcN appears to be inhibited
by combined dosing with CS. Further research directed to-
wards understanding the possible indirect effects of these
agents22 on joint health appears to represent the most pro-
ductive way forward at present23.Fig. 6. The effect of pre-dosing on the concentration proﬁle for a sin-
gle dose of CS. The plasma concentration of CS following a single
dose of CS (1200 mg) after 3 months of pre-dosing with GlcN (open
squares), CS (closed diamonds) or GlcNþCS (closed squares).
Also shown (closed triangles) is the control data without CS dosing.Conﬂict of interest
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